Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reversing there nicely
It's coming
Bouncing back
Nine States with Ballot Initiatives, Marks Emerging Growth
MIAMI, FL / ACCESSWIRE / October 18, 2016 / Novus Acquisition and Development Corp. (OTC Markets: NDEV), the nation's first healthcare insurance carrier in the medical cannabis field and property and casualty sector, provides its status and positioning on the upcoming November 8 state ballots and cannabis healthcare. Novus CEO Frank Labrozzi offers a summary update to the upcoming cannabis state ballots and his view and the company's positioning for the future of cannabis in the United States.
On November 8, less than a month away, marijuana state ballot initiatives are all pointing toward voter approval. These ballot initiatives will likely reshape the cannabis industry in the U.S. with legalization and recreational proposals in Arizona, California, Maine, Massachusetts and Nevada and medical marijuana proposals in Arkansas, Florida, Montana and North Dakota.
According to the Organization for Reform of Marijuana Laws, polls show that approval percentages in Arizona are over 50%, Nevada 57% and California overwhelming 60%, Maine and Massachusetts with over 53%. In fact, a recent September 12, 2016 Cowen and Company Collaborative Insights Report titled, The Cannabis Compendium: Cross-Sector Views on a Budding Industry, believes that California passing recreational has an 80% probability.
Novus shareholders should know that Novus's footprint in the cannabis sector is Washington, Oregon, Arizona, California, Nevada, Colorado and Michigan. Additionally, the states that are up and coming that Novus will be entering into post election are Illinois, Massachusetts, Pennsylvania and Maine. Novus is well-positioned to take advantage of increased legalization of cannabis, both recreational and medical.
If all five state ballot initiatives were to pass, the percentage of U.S. population and GDP captured by recreational states would be 23% and 26%, respectively. A California recreational approval, which is already estimated to be a $1 billion medical marijuana market, would add an approximate 39 million people to the number of Americans living in a state legalized for recreational cannabis, tripling the market in the U.S.
These aforementioned states, the percent of the U.S. population and GDP covered by recreational states would grow expenditally. While Novus' full business potential in legal cannabis space and in the healthcare sector is now well into focus, early indicators suggest that the potential is considerable. Indeed, it is arguably in healthcare that legal cannabis could make its first big crossover to the mainstream marketplace.
Despite the current barriers that hinder the progress of cannabis healthcare what is encouraging is consumer demand for existing medical cannabis products primarily for pain. Giving our government and healthcare professionals comfort to know that is can significantly reduce addiction to, and deaths from, opioid painkillers could bolster cannabis's credibility as a legitimate healthcare product as an opioid replacement.
As full federal legalization maybe some time in the future, policy is already shifting with relaxed restriction coming from the DEA it will now be up to Congress to make cannabis part of the healthcare mainstream. And when this happens, history has shown the one thing that biotechnology and pharmaceuticals have in common is they are always dove tailed within health insurance.
NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj
Website: http://www.getnovusnow.com
Investor Relations Website: http://www.getnovusnow.com/ndev/investor_page
About Novus
Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector.
Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.
The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.
For more information, check out: http://www.getnovusnow.com
For NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj
Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva
Forward-Looking Statements
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
Corporate:
Chairman and CEO
Frank Labrozzi
frank@ndev.biz
855-228-7355
Investors:
Hayden IR
hart@haydenir.com
917-658-7878
SOURCE: Novus Acquisition and Development Corp.
The 2012 MMJ boom had pretty much died up until this year. This is going to be a fun ride, up another 50% today :)
I was gonna say the same thing. FML I only loaded 10k at 0.17 GLTYA
BULL$$$ gaining momentum here folks
And IMO this is going to be the geico of MMJ industry in the 3-5 years
Hey Charlie, glad you hoped on this northbound train yesterday just in time.
Anyone watching L2, how thin is it?
13 mins and almost $350 grand traded
The shorts don't understand the imminent implant of MMJ legalization as medicinal and recreational. 90% of the North American population smoke or have tried smoking weed in their lifetime
Who's pumping this POS???
You do make sense but what if the company has actual higher cost of operating than profits? I know last year they made $1,000,000 and the cost as $2,000,000, but I know a thousand other companies that didn't make ANY profit in the first 24-36 months. Dilutions MIGHT have been to generate more capital in order to stabilize a newly growing company. What's the proof that DP and company holder dilute the shares for personal gains and are corrupt??
I never said anything about that. Ever heard of a newly growing company on the right path? It did, ALMOST, drop all the way to the 52 week support tho! But the reversing and imminent legalization of MMJ is gonna make this baby run. Cover your shorts before its too late.
Welcome aboard comrade!!!!
DP is on fire. His intellect and charm are evident of his hard work. He truly believes in the company he's in charge of and is working hard towards expanding the newly growing business. Haters are those with short positions and loosing sleep. To cover they'll need to either wait till the first quarterly of 2017 or cover their losses as of now.
Breaking the 52 week moving average as if it was a mundane affair for this low floater. Shorts are loosing sleep, long are loosing sleep, but the seasoned ones can see the pE=mgh on this LOW FLOATER and are accumulating. I haven't heard anything about insiders buying shares back, if you've heard anything about it then please let me know. Yes, two R/S with the latest one in 2013 and that's 3 years ago, almost 4 years. THE MMJ HYPE and the upcoming elections are a super-catalyst for this LOW FLOATER. Nine(9) states are voting for the legalization of MMJ and four(4) of them are voting for recreational legalization. The stats say that 90% of North Americans either do or have tried marijuana in their lifetime. I personally use MJ for an injury to my back and the pain associated with it. Tell me how taking T3 for pain is better than taking MJ. But the gist of it is that MJ/MMJ is an industry about to get reincarnated, I don't even want to start about the by products and the benefits of the Cannabis family of plants. ANY BUSINESS related to the MMJ industry is poised to perform like gold companies during a gold rush. IMO this baby $NDEV is poised to run north towards at least $1.10 by the first quarterly of 2017. If you disagree then please tell me why is the case. I always appreciate a nice constructive criticism.
BE HONEST!!
Is there anyone else loosing the ability to fall asleep over this? I've not seen a low float runner like this in at least 3-4 years. GLTYA
This is poised to become the Geico of MMJ industry. With the MMJ vote and hype along with the acquisition of providers that'll cover the businesses related to the MMJ industry $NDEV isn't is ready to take off. And seems like no RS at least until 2nd quarterly of 2017 imo
Welcome aboard.
A/S 200M
I/S 91M
Float 14M
New staff hired to increase manpower and profitability. It's time to watch this baby ride north
Impatient sellers looking for lunch money
434M bid 0001
10M ask 0002
Ready for take off.
A/S = 2B
O/S = 968M
Float = 400M
Market Cap = 194K
I ABSOLUTELY do not mean to question the experience and intelligence of the seasoned/hardcore traders, but...those numbers should be lookin f$$$in insane to anyone! Enjoy the ride north, given we have volume.
Is the float still 4.2B?
Bid 430 mil @.0001
Impatient bunch of sellers
Probably a PR about that on October 18th is what I read somewhere
Trade restriction on Questrade, wtf? Anyone else??
The company's Altman Z-Score is -3.98, indicating that it is in the distress zone and there is a possibility of bankruptcy in the next two years.
The company's Sloan ratio is (-25.61%) higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
The company's per share revenue has been in decline at an average rate of -37% per year.
The company continues to issue new long-term debt. Over the previous three years, it has issued $0.326 million of debt.
Missed entry at .55 :(((
Even the cousin Canadian, along with, American medical marijuana stocks are strongly poised to run 2000%-4000% by the end of 2016 and the first quarterly of 2017. Accumulate while you can.
http://globalnews.ca/news/2995390/canada-will-see-900000-new-pot-smokers-under-legalization-poll-implies/amp/
"IF" the said 900,000 Canadian medical marijuana users, legally, buy a quarter (1/4th) of an ounce (7.0 grams) of medical marijuana in the first month of the 2017 legalization of Canada wide medical marijuana, at an average of $10/gram, the math works out to be $54,000,000 CAD for the said month. The effects will be astronomical on Canadian and cousin American medical marijuana stocks specially the companies operating in all of North America.
Accumulate while you can. I predict a 1000% run by the end of 2016.
I can't f$$$in' sleep!
http://mobile.reuters.com/article/amp/idUSKCN12C2P4
Medical Marijuana legalization gains strong support from majority public.
News of forward split, preffered dilution proof B-shares and legalization of medical marijuana just around the corner. 11/11/2016 mark that date on you calendar.
AMEN
Hmm will check with broker. $MRNJ added another mill too